Q1 2017 TESARO Inc Earnings Call

9/5/2017 16:15

Conference Call TESARO Inc

TESARO Inc Conference call or earnings call will be held on May 9, 2017 During the earnings conference call's session TESARO Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact TESARO Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. We were founded in March 2010 and have in-licensed and are developing oncology-related product candidates, including rolapitant and niraparib, as well as product candidates under our immuno-oncology platform. On September 1, 2015, our first commercial product, VARUBI® (rolapitant), was approved by the United States Food and Drug Administration, or FDA, for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited 4 -------------------------------------------------------------------------------- Table of Contents to, highly emetogenic chemotherapy.    
Read more Conference Call

TESARO Inc (TSRO)

1000 Winter Street, Waltham Massachusetts 02451, United States